From January to April 2017, we have seen promising financial indicators for both private and public life science companies.  On the venture side, Twist Biosciences announced a $33M raise which brings it to a total of $166M to date.  Cash can be a significant competitive advantage when building a company in highly transformative markets, like Synthetic biology, and Gene editing (e.g., using CRISPR).   Just last week, Two Pore Guys, a new company that has developed a hand-held nanopore sensor raised $24.5 M in a Series A round...